Insulet (PODD) AI Stock Analysis

• Market Cap: $20.00B
• Dividend Yield: N/A
• Average Volume (3M): 711.14K
• Price to Earnings (P/E): 50.6
• Beta (1Y): 1.10
• Revenue Growth: 23.49%
• EPS Growth: 71.25%
• Country: US
• Employees: 3,900
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): 1.02
• Shares Outstanding: 70,374,920
• 10 Day Avg. Volume: 496,654
• 30 Day Avg. Volume: 711,136
• PEG Ratio: -12.81
• Price to Book (P/B): 15.36
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 70.35
• Enterprise Value/Market Cap: 0.96
• Enterprise Value/Revenue: 2.36
• Enterprise Value/Gross Profit: 12.41
• Enterprise Value/Ebitda: 11.40
• 1Y Price Target: $340.84
• Price Target Upside: 19.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 21

• Rating: 70 Outperform
• Price Target: $312.00 ▲(9.26%Upside)

Insulet's strong financial performance and positive earnings call contribute significantly to its score. However, bearish technical indicators and a high valuation weigh down the overall assessment. The recent positive corporate event also boosts the outlook.

Positive Factors

Financial Performance

PODD raised its worldwide Omnipod constant currency sales growth guidance to 20-23%, up from a previous range of 17-21%.

Innovation and Growth

Insulet is experiencing robust growth from the Type 2 launch, at an early stage in the adoption curve.

Market Position

PODD is recognized as a market leader in the pump market, bolstered by sensor integrations and entry into new markets.

Negative Factors

Competitive Environment

PODD's premium trading price may reflect challenges in maintaining its competitive edge and high growth rate.

Insulet Business Overview & Revenue Model

Company Description

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, and Australia. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

How the Company Makes Money

Insulet makes money through the sale of its Omnipod Insulin Management System, which includes both the wearable pods and the associated Personal Diabetes Manager (PDM). The company generates revenue primarily from the sale of these consumable pods, which need to be replaced every few days, creating a recurring revenue model. Additionally, Insulet may earn revenue from partnerships and collaborations with healthcare providers, insurance companies, and other stakeholders in the diabetes management ecosystem. The company's earnings are also influenced by its ability to expand its customer base, market its products effectively, and innovate within the insulin delivery space.

Insulet Financial Statement Overview

Summary

Insulet exhibits strong financial performance with consistent revenue growth and improved profitability. The balance sheet is solid with low leverage and high equity returns, while cash flow management is effective, providing a good cushion for future investments. However, there is room for improvement in maximizing margins and optimizing capital allocation.

Income Statement

Insulet has demonstrated strong revenue growth, particularly noticeable in its TTM (Trailing-Twelve-Months) performance with a significant increase over previous years. The gross profit margin is robust at approximately 76.5%, indicating efficient production management. The net profit margin and EBIT margin have also improved, reflecting enhanced operational efficiency and profitability. However, compared to some industry peers, there is scope for further improvement in EBIT and EBITDA margins.

Balance Sheet

The balance sheet shows a solid equity position with a debt-to-equity ratio of approximately 0.06, indicating low financial leverage and risk. Insulet's return on equity (ROE) is impressive at approximately 30.22%, showcasing strong shareholder returns. The equity ratio is about 37.8%, affirming a stable financial structure, although there is room to enhance asset utilization.

Cash Flow

Insulet's cash flow management is commendable with positive free cash flow and a healthy operating cash flow to net income ratio. The free cash flow growth is stable, contributing to financial flexibility. However, there is potential to optimize capital expenditures further to enhance free cash flow generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	2.07B	1.70B	1.31B	1.10B	904.40M
Gross Profit	1.45B	1.16B	805.60M	752.10M	582.30M
EBITDA	423.70M	323.60M	109.50M	139.60M	110.30M
Net Income	418.30M	206.30M	4.60M	16.80M	6.80M
Balance Sheet
Total Assets	3.09B	2.59B	2.25B	2.05B	1.87B
Cash, Cash Equivalents and Short-Term Investments	953.40M	704.20M	674.70M	791.60M	947.60M
Total Debt	1.39B	1.42B	1.40B	1.25B	1.04B
Total Liabilities	1.88B	1.86B	1.77B	1.49B	1.27B
Stockholders Equity	1.21B	732.70M	476.40M	556.30M	603.60M
Cash Flow
Free Cash Flow	305.40M	36.50M	-38.30M	-190.80M	-82.50M
Operating Cash Flow	430.30M	145.70M	119.00M	-68.10M	84.00M
Investing Cash Flow	-146.20M	-119.40M	-191.10M	-82.70M	14.00M
Financing Cash Flow	-28.10M	-13.60M	-40.30M	40.70M	605.50M

Insulet Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 285.57
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For PODD, the sentiment is Negative. The current price of 285.57 is below the 20-day moving average (MA) of 298.24, below the 50-day MA of 307.56, and above the 200-day MA of 271.77, indicating a neutral trend. The MACD of -5.75 indicates Positive momentum. The RSI at 30.67 is Neutral, neither overbought nor oversold. The STOCH value of 4.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for PODD.

Insulet Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SNN	80 Outperform	$13.27B	31.95	7.86%	2.48%	5.16%	56.79%
DXCM	78 Outperform	$32.89B	63.08	23.72%	―	9.11%	-17.87%
STE	71 Outperform	$22.19B	35.55	9.46%	1.02%	0.32%	64.36%
PODD	70 Outperform	$20.00B	50.56	37.92%	―	23.49%	71.25%
Sector *	52 Neutral	$7.37B	-0.04	-63.81%	2.59%	16.40%	<0.01%
PHG	51 Neutral	$23.70B	―	-7.10%	3.61%	-0.76%	-55.03%
TNDM	48 Neutral	$983.79M	―	-92.31%	―	27.65%	-28.22%

Insulet Corporate Events

Insulet Issues Redemption Notice for Convertible Notes

On June 6, 2025, Insulet Corporation amended its Credit Agreement to refinance $481.25 million in term loans, reducing the interest rate margin and maintaining similar terms to the previous loans. Additionally, Insulet issued a redemption notice on June 9, 2025, for its outstanding Convertible Senior Notes due 2026, with plans to redeem them by August 20, 2025, potentially impacting stock transactions as hedge positions are unwound.

The most recent analyst rating on (PODD) stock is a Buy with a $380.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Corporation Holds 2025 Annual Stockholders Meeting

Insulet Corporation held its 2025 Annual Meeting of Stockholders on May 22, 2025, where shareholders elected three Class III directors, approved executive compensation, and ratified the appointment of Grant Thornton LLP as the independent public accounting firm for the fiscal year ending December 31, 2025. Additionally, the Insulet Corporation 2025 Stock Option and Incentive Plan was approved, indicating continued shareholder support for the company’s strategic initiatives and governance practices.

The most recent analyst rating on (PODD) stock is a Hold with a $185.00 price target. To see the full list of analyst forecasts on Insulet stock, see the PODD Stock Forecast page.

Insulet Appoints Ashley McEvoy as New CEO

On April 28, 2025, Insulet Corporation announced the appointment of Ashley McEvoy as President and CEO, succeeding Jim Hollingshead. This leadership change is expected to further the company’s success, as McEvoy brings extensive experience in healthcare leadership and innovation. Under Hollingshead’s tenure, Insulet achieved market leadership in diabetes care with the launch of the Omnipod 5. The company also announced it expects to exceed its first-quarter revenue guidance and plans to raise its full-year 2025 guidance, indicating strong financial performance and growth potential. The planned Investor Day has been postponed due to the CEO transition.